Related references
Note: Only part of the references are listed.Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy
A. L. Noordhof et al.
LUNG CANCER (2021)
Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations
Martin Reck et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2020)
Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma
Masatoshi Kudo
CANCERS (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Relationship between STK11 and KEAP1 mutational status and efficacy in KEYNOTE-042: pembrolizumab monotherapy versus platinum-based chemotherapy as first-line therapy for PD-L1-positive advanced NSCLC
Byoung Chul Cho et al.
CANCER RESEARCH (2020)
STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort
Simon Papillon-Cavanagh et al.
ESMO OPEN (2020)
Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
Arnaud Jeanson et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
Martin Reck et al.
LANCET RESPIRATORY MEDICINE (2019)
KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
Helen Adderley et al.
EBIOMEDICINE (2019)
New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
Haitang Yang et al.
FRONTIERS IN ONCOLOGY (2019)
LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in KEYNOTE-042
R S Herbst et al.
ANNALS OF ONCOLOGY (2019)
LBA5 KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC
S Gadgeel et al.
ANNALS OF ONCOLOGY (2019)
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Ferdinandos Skoulidis et al.
NATURE REVIEWS CANCER (2019)
Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
Priti S. Hegde et al.
SEMINARS IN CANCER BIOLOGY (2018)
KRAS-Mutant non-small cell lung cancer: From biology to therapy
Irene Ferrer et al.
LUNG CANCER (2018)
Combinations of Bevacizumab With Cancer Immunotherapy
Daniel S. Chen et al.
CANCER JOURNAL (2018)
Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer
Kathryn C. Arbour et al.
CLINICAL CANCER RESEARCH (2018)
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Zhong-Yi Dong et al.
CLINICAL CANCER RESEARCH (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients
E. C. Martino et al.
CELL DEATH DISCOVERY (2016)
Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2015)
LKB1 Loss Induces Characteristic Patterns of Gene Expression in Human Tumors Associated with NRF2 Activation and Attenuation of PI3K-AKT
Jacob M. Kaufman et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)
S. Dearden et al.
ANNALS OF ONCOLOGY (2013)
Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
Laurence Zitvogel et al.
IMMUNITY (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo
Alison M. Paterson et al.
JOURNAL OF IMMUNOLOGY (2011)
The Novel Costimulatory Programmed Death Ligand 1/B7.1 Pathway Is Functional in Inhibiting Alloimmune Responses In Vivo
Jun Yang et al.
JOURNAL OF IMMUNOLOGY (2011)
B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance
Jang-June Park et al.
BLOOD (2010)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
Manish J. Butte et al.
IMMUNITY (2007)
Share Paper
